James A. Joyce, Executive Chairman
Jim Joyce is the founder of Exosome Sciences and founder, Chairman and CEO of Aethlon Medical (Nasdaq:AEMD), which maintains majority ownership in Exosome Sciences. Under Mr. Joyce’s leadership, Aethlon pioneered the creation of affinity biofiltration devices to treat life-threatening diseases. Time magazine recently named the Aethlon Hemopurifier® to be one of the “Top 25 Inventions” and one of “11 Remarkable Advances in Healthcare” based on the Hemopurifier”s ability to address a broad-spectrum of viral pathogens, including the successful treatment of Ebola virus. In the field of exosome biology, Jim has co-authored exosome-related publications and is co-inventor on exosome-specific patent submissions. Prior to founding Exosome Sciences and Aethlon Medical, he was Managing Director at James Joyce & Associates, founder and CEO of Mission Labs, Inc. and was a member of the Denver Broncos Football Club of the National Football League. Jim is a graduate of the University of Maryland.
James B. Frakes, Interim Chief Financial Officer
Since 2008, Mr. Frakes has served as CFO of Aethlon Medical, Inc., a publicly traded organization that maintains a majority ownership position in Exosome Sciences. Mr. Frakes received an MBA from the University Southern California, and completed his BA with Honors at Stanford University.